...
首页> 外文期刊>Cell death & disease. >AID modulates carcinogenesis network via DNA demethylation in bladder urothelial cell carcinoma
【24h】

AID modulates carcinogenesis network via DNA demethylation in bladder urothelial cell carcinoma

机译:通过DNA去甲基化在膀胱尿路上皮细胞癌中调节致癌网络

获取原文
           

摘要

Bladder cancer is one of the most common malignant diseases in the urinary system, with poor survival after metastasis. Activation-induced cytidine deaminase (AID), a versatile enzyme involved in antibody diversification, is an oncogenic gene that induces somatic hypermutation and class-switch recombination (CSR). However, the contribution of AID-mediated DNA demethylation to bladder urothelial cell carcinoma (BUCC) remains unclear. Herein, we evaluated the impact on BUCC caused by AID and explored the gene network downstream of AID by using a proteomic approach. Lentiviral vector containing AID-specific shRNA significantly reduced AID expression in T24 and 5637 cells. Silencing AID expression remarkably inhibited tumour malignancies, including cell proliferation, invasion and migration. We used Isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomics analysis technology to study the underpinning mechanism in monoclonal T24 cells, with or without AID knockdown. Among the 6452 proteins identified, 99 and 142 proteins in shAICDA-T24 cells were significantly up- or downregulated, respectively (1.2-fold change) compared with the NC-T24 control. After a pipeline of bioinformatics analyses, we identified three tumour-associated factors, namely, matrix metallopeptidase 14 (MMP14), C–X–C motif chemokine ligand 12 and wntless Wnt ligand secretion mediator, which were further confirmed in human BUCC tissues. Nonetheless, only MMP14 was sensitive to the DNA demethylation molecule 5-aza-2’-deoxycytidine (5-azadC; 5?μM), which reversed the inhibition of carcinogenesis by AID silence in T24 and 5637 cells. Overall, AID is an oncogene that mediates tumourigenesis via DNA demethylation. Our findings provide novel insights into the clinical treatment for BUCC.
机译:膀胱癌是泌尿系统中最常见的恶性疾病之一,转移后存活差。活化诱导的胞苷脱氨酶(AID),涉及抗体多样化的通用酶,是诱导体细胞高压和转换重组(CSR)的致癌基因。然而,辅助介导的DNA去甲基化对膀胱尿路上皮细胞癌(BUCC)的贡献仍不清楚。在此,我们评估了通过助剂引起的对BUCC的影响,并通过使用蛋白质组学方法探讨了辅助下游的基因网络。携带辅助载体的辅助载体在T24和5637细胞中显着减少了助剂表达。沉默援助表达显着抑制肿瘤恶性肿瘤,包括细胞增殖,入侵和迁移。我们使用了相对和绝对定量(ITRAQ)的等离标签 - 基于蛋白质组学分析技术,以研究单克隆T24细胞的支撑机制,有或没有援助敲低。在与NC-T24对照相比,鉴定的6452蛋白蛋白质中鉴定的99和142个蛋白分别显着上调(1.2倍变化)。在生物信息学分析的管道之后,我们确定了三种肿瘤相关因素,即基质金属肽酶14(MMP14),C-X-C基序趋化因子配体12和WNTless Wnt配体分泌介质,其在人BUCC组织中进一步证实。尽管如此,只有MMP14对DNA去甲基化分子5-AZA-2'-脱氧胞苷(5-α-脱氧胞嘧啶(5-αμm)敏感,这通过T24和5637细胞助使静音逆转了致癌癌的抑制。总的来说,援助是一种癌基因,通过DNA去甲基化介导肿瘤内血。我们的调查结果为BUCC的临床治疗提供了新的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号